52 research outputs found

    Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels

    Get PDF
    The study tests the hypothesis that in patients admitted with acutely decompensated heart failure (ADHF), achievement of adequate body hydration status with intensive medical therapy, modulated by combined bioelectrical vectorial impedance analysis (BIVA) and B-type natriuretic peptide (BNP) measurement, may contribute to optimize the timing of patientā€™s discharge and to improve clinical outcomes. Three hundred patients admitted for ADHF underwent serial BIVA and BNP measurement. Therapy was titrated to reach a BNP value of <250Ā pg/ml, whenever possible. Patients were categorized as early responders (rapid BNP fall below 250Ā pg/ml); late responders (slow BNP fall below 250Ā pg/ml, after aggressive therapy); and non-responders (BNP persistently >250Ā pg/ml). Worsening of renal function (WRF) was evaluated during hospitalization. Death and rehospitalization were monitored with a 6-month follow-up. BNP value on discharge of ā‰¤250Ā pg/ml led to a 25% event rate within 6Ā months (Group A: 17.4%; Group B: 21%, Chi2; n.s.), whereas a value >250Ā pg/ml (Group C) was associated with a far higher percentage (37%). At discharge, body hydration was 73.8Ā Ā±Ā 3.2% in the total population and 73.2Ā Ā±Ā 2.1, 73.5Ā Ā±Ā 2.8, 74.1Ā Ā±Ā 3.6% in the three groups, respectively. WRF was observed in 22.3% of the total. WRF occurred in 22% in Group A, 32% in Group B, and 20% in Group C (PĀ =Ā n.s.). Our study confirms the hypothesis that combined BNP/BIVA sequential measurements help to achieve adequate fluid balance status in patients with ADHF and can be used to drive a ā€œtailored therapy,ā€ allowing clinicians to identify high-risk patients and possibly to reduce the incidence of complications secondary to fluid management strategies
    • ā€¦
    corecore